CEL-SCI Reports 146 Patients Enrolled in Its Phase III Immunotherapy Head and Neck Cancer Trial
CEL-SCI Corporation reported accelerating progress in patient enrollment in the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection). Approximately 146 patients have been enrolled in the Phase III study to date.
View full press release